Reference : Le medicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogesterone) c...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
http://hdl.handle.net/2268/99488
Le medicament du mois. Femoston Low (0,5 mg d'estradiol plus 2,5 mg de dydrogesterone) comme traitement hormonal de substitution a la menopause.
French
[en] Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy
SCHEEN, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques]
Gaspard, Ulysse mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)]
2011
Revue Médicale de Liège
66
4
209-14
Yes (verified by ORBi)
0370-629X
Belgium
[en] Drug Combinations ; Dydrogesterone/pharmacology ; Estradiol/pharmacology ; Estrogen Replacement Therapy ; Female ; Humans
[en] Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Researchers ; Students
http://hdl.handle.net/2268/99488
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
8. SCHEEN Med Femoston (6).pdfPublisher postprint181.62 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.